NL-OMON20157
Recruiting
Not Applicable
A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine and Protocolized Surgery in Resectable Gastric Cancer. An IKZ-based phase II feasibility study.
dr K. Bosscha, surgeondr J.F.M. Pruijt, oncologistdrs A.E. Dassen, resident in training for surgery0 sites50 target enrollmentTBD
ConditionsResectable/curable gastric cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Resectable/curable gastric cancer
- Sponsor
- dr K. Bosscha, surgeondr J.F.M. Pruijt, oncologistdrs A.E. Dassen, resident in training for surgery
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
/A
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Ib\-IVa histological proven resectable gastric adenocarcinoma, including gastro\-oesophageal junction/cardia carcinoma;
- •2\. Siewert 2 and 3;
Exclusion Criteria
- •1\. Inoperable patients;
- •2\. Previous or other current malignancies, with the exception of adequately treated in situ carcinoma of the cervix uteri or non\-melanoma skin cancer;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine and Protocolized Surgery in Resectable Gastric Cancer An IKZ-based phase II feasibility studygastric cancergastric carcinoma100179901001799110017998NL-OMON31603Jeroen Bosch Ziekenhuis50
Active, not recruiting
Not Applicable
A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine combined with Protocolized Surgery in Resectable Gastric Cancer - DoCCSEUCTR2007-007273-23-NLJeroen Bosch Hospital
Completed
Phase 2
Phase II study of neoadjuvant and adjuvant docetaxel/cisplatin/5-fluorouracil in resectable esophagus canceresophagus cancerJPRN-UMIN000005588Jikei university of medicine department of surgery, department of oncology and hematology12
Recruiting
Phase 2
eoadjuvant DOS treatment for advanced esophageal cancerJPRN-jRCTs041210023Kodera Yasuhiro45
Not yet recruiting
Phase 2
Multicenter phase II study of neoadjuvant chemotherapy of gemcitabine+nab-paclitaxel therapy for patients with resectable pancreatic cancer.Invasive ductal adenocarcinomaJPRN-UMIN000028101Division of Hepato-biliary-pancreatic Surgery Department of Surgery, Kobe University Graduate School of Medicine45